Tag Archives: Recalled

Hawaii Department of Health warns consumers

Hawaii Department of Health warns consumers

HONOLULU – The Hawai‘i State Department of Health (DOH) is alerting residents and visitors that Johnson & Johnson Consumer Inc. (JJCI) is voluntarily recalling all lots of five NEUTROGENA® and AVEENO® aerosol sunscreen product lines. Company testing identified low levels of benzene in some samples of the products. Consumers should stop using the affected products and discard or return them.

The recalled products are spray-on sunscreens, specifically:

  • NEUTROGENA® Beach Defense® aerosol sunscreen,
  • NEUTROGENA® Cool Dry Sport aerosol sunscreen,
  • NEUTROGENA® Invisible Daily™ defense aerosol sunscreen,
  • NEUTROGENA® Ultra Sheer® aerosol sunscreen, and
  • AVEENO® Protect + Refresh aerosol sunscreen.

Product images and lot information is available at www.neutrogena.com and www.aveeno.com.

The recalled sunscreens are packaged in aerosol cans and were distributed nationwide, including Hawai‘i, through a variety of retailers. Three of the affected sunscreens contain oxybenzone and/or octinoxate, ingredients banned from sale or distribution in Hawai‘i under Section 11-342D-21, Hawaii Revised Statutes, that went into effect in January 2021.

Benzene, the chemical found in the affected sunscreens, is common in the environment including in motor vehicle exhaust and cigarette smoke, and is known to cause cancer in humans. Benzene is not an ingredient in sunscreen products and the levels of benzene found in the recalled products was low. Based on current information, daily exposure to benzene in these sunscreen products would not be expected to cause adverse health consequences. However, these products are being recalled to prevent further exposure. JJCI is investigating the possible cause of contamination that led to the presence of benzene in their products.

Sunscreen use is critical to public health and the prevention of skin cancer. People should continue to take appropriate sun protection measures including using reef safe sunscreens, covering skin with clothing and hats, and avoiding the sun during peak hours.

Consumers may contact the JJCI Consumer Care Center 24/7 with questions or to request a refund by calling 1-800-458-1673. Consumers should contact their physician or healthcare provider if they have any questions, concerns or have experienced any problems related to using these aerosol sunscreen products. JJCI is also notifying its distributors and retailers by letter and is arranging for returns of all recalled products.

# # #

Read more
This post originally posted here The European Times News

Dog food recalled over salmonella contamination and risk to human health – full list

The latest pet food recall comes from Natural Instinct Ltd who is recalling several dog food products containing duck because salmonella has been found in the products. Experts warn that the bug, which can cause serious illness in humans, can be passed from pets to their owners.

Products being recalled:

Working Dog Duck

Pack size – 1kg and 2x500g

Use by – January 8, 2022, January 15, 2022, January 22, 2022, February 13, 2022, February 20, 2022, March 11, 2022 and March 18, 2022

Pure Duck

Pack size – 1kg and 2x500g

Use by – January 8, 2022, January 15, 2022, January 22, 2022, February 13, 2022, February 20, 2022, March 11, 2022 and March 18, 2022

Working Dog Puppy

Pack size – 1kg and 2x500g

Use by – January 15, 2022, January 22, 2022, February 12, 2022, February 20, 2022 and March 11, 2022

Shoppers ‘amazed’ by Sainsbury’s new recycling system [COMMENT]
Monty Don: Amazing natural pest remover to kill slugs and snails [EXPERT]
Royal Mail ‘considering’ asking people to use different letterboxes [INSIGHT]

Duck Carcass

Pack size – Pack of two

Use by – January 8, 2022, January 15, 2022 and February 20, 2022

Duck Necks

Pack size – Pack of six

Use by – January 15, 2022 and January 22, 2022

The FSA added: “If you have bought any of the above products do not use them. Instead, return them to the store from where they were bought for a full refund.

“When handling and serving raw pet food it is always advised to clean utensils and feeding bowls thoroughly after use.

“Consumers should wash hands thoroughly after handling raw pet food, utensils or after contact with faces of animals.

“Raw pet food should be stored separately from any food (especially ready to eat food). Care should be taken when defrosting to avoid cross contamination of foods and surfaces.”

The US Food and Drug administration said: “Salmonellosis is uncommon in dogs and cats, but they can be carriers of the bacteria.

“This means that even if pets don’t show symptoms of salmonellosis, they can still shed salmonella in their stool and saliva and then spread the bacteria to the home environment and to people and other pets in the household.

“Some ways dogs can spread the bacteria is when they give people kisses or have stool accidents inside the home. Pet waste from both sick and healthy pets can be a source of infection from people.”

The FSA added: “If there is a problem with a food product that means it should not be sold, then it might be ‘withdrawn’ (taken off the shelves) or ‘recalled’ (when customers are asked to return the product.”

It comes just weeks after several batches of cat food were recalled over the potential link of a deadly cat disease.

The FSA and the department for Environment, Food and Rural Affairs have warned cat owners not to give their pets fry food made on behalf of the brands by manufacturer Fold Hill Foods. 

This is due to an outbreak of pancytopenia, an illness that can be fatal in felines. 

The condition causes a rapid decline in the number of blood cells.

Author: Sophie Harris
Read more here >>> Daily Express :: Life and Style
Read More

Blood pressure pills recalled after discovery of explosive chemical that causes cancer

In a dramatic turn of events, health chiefs have recalled dozens of blood pressure pills that are deemed to pose a grave public health risk. The drugs in question — several different types of irbesartan and losartan – have been recalled from pharmacy shelves because they contain azido-tetrazole. The substance is considered by some health experts to be the world’s most explosive chemical and is linked to a heightened risk of cancer.

The Medicines and Healthcare products Regulatory Agency (MHRA) – the UK’s drug oversight body – said the explosive substance is found in batches of the aforementioned blood pressure pills.

At this stage, the recall is merely precautionary and there was no proof it has caused any harm to patients, the MHRA said in a statement.

The health body urged Brits to not stop taking the drugs without consulting their GP because suddenly stopping can be pose health risks.

Some of the contaminated pills have been on the market for nearly two years, it was also revealed.

READ MORE: High blood pressure: The surprising food increasing your risk of hypertension

As the Mail Online reports, the latest development follows a series of drug recalls of sartan-type medicines, which may have been exposed to cancer-causing chemicals in factories in China and India.

Irbesartan and losartan are prescribed to millions of Britons with high blood pressure every year.

Commenting on the decision, Dr June Raine, MHRA Chief Executive, said: “Patient safety is our watchword. We’re recalling batches of certain sartan-containing products as a precautionary measure while we continue our investigation. It’s important that healthcare professionals check their stock to quarantine and return these batches.

“If you’ve been taking one of the affected products, speak with your doctor or pharmacist before stopping any treatment – they can address any concerns and can advise you on the best course of action.”

High cholesterol: Three symptoms in your eyes [ADVICE]
Phil Collins health: ‘I was very close to dying’ [INSIGHT]
Fatty liver disease: Four signs on your hand [TIPS]

According to Public Health England, previous recalls of these types of products in 2018 and 2019 are part of an ongoing investigation.

The MHRA also said it is working with other medicines regulators on this issue.

There is currently no evidence any of the pills have exploded.

The MHRA said the move only applied to pharmacies and wholesalers stocking the 31 batches supplied by Bristol Laboratories Limited, Brown & Burk UK Limited and Teva UK Limited, some of which were first distributed in September 2019.

It is important to note that other blood pressure pills containing losartan and irbesartan are still available.

Dr Raine of MHRA also issued important advice if you’re taking the affected blood pressure pills or stocking them.

She said: “It’s important that healthcare professionals check their stock to quarantine and return these batches.

“If you’ve been taking one of the affected products, speak with your doctor or pharmacist before stopping any treatment – they can address any concerns and can advise you on the best course of action.”

The health risk posed by the substance azido-tetrazol was alerted to the world by Cambridge University chemical scientist Dr Ljiljana Fruk.

Dr Fruk described azido-tetrazole as the the world’s “most explosive chemical” in 2019.

Speaking on the The Naked Scientists radio show at the time, she said: “So the most explosive chemical was made in 2011 in the lab.

“[It] Never went out of the lab, it was made in a special chamber and it’s called azido-tetrazole.

“So that’s a molecule that has 14 nitrogens in its own structure, and because of these constrained nitrogen bonds it’s very explosive.”

This post originally appeared on Daily Express :: Health Feed
Read More

Co-codamol tablets recalled: Users asked to check packaging after safety concerns

Batch number 1K10121 of a co-codamol painkiller is being recalled for safety concerns as they potentially have too little or too much of the active ingredients – codeine phosphate and paracetamol. Having too little of the ingredients causes the painkillers not to work as they should do. In addition, the lucky dip of pills may contain too much of the ingredients, which can lead to an overdose.

Current advise is “not to take any tablets from these packs given the potential risks of doing so”.

Healthcare professionals are also instructed to check their stocks and recall tablets from this batch “urgently”.

Batch 1K10121 details

  • Co-codamol 30/500 Effervescent Tablets
  • Company Name: Zentiva Pharma UK Ltd
  • PL 17780/0046
  • Batch Number: 1K10121
  • Expiry Date: December 2023
  • Pack Size: 100 tablets
  • Batch Size: 4464 packs
  • First Distributed: 05 March 2021

There are 4,464 packs under the batch number 1K10121 that are being recalled due to safety concerns.

What is co-codamol?

The NHS explained co-codamol is a mixture of paracetamol and codeine.

The medication is usually taken to treat headaches, muscular pain, migraines, and toothache.

Common side effects of co-codamol can include:

  • Constiaption
  • Nausea
  • Feeling sleepy.

Adults and children over the age of 12 are able to take co-codamol, but it’s unsuitable if you:

  • Have lung problems or breathing difficulties
  • Have a head injury
  • Have adrenal gland problems
  • Have a condition that causes fits or seizures
  • Regularly drink more than the maximum recommended amount of alcohol (14 units a week)
  • Are trying to get pregnant, are already pregnant or are breastfeeding
  • Have liver problems – you may need to take a lower dose
  • Are under 18 years old and have had your tonsils or adenoids removed because of a sleep problem called obstructive sleep apnoea.

Co-codamel comes in different strengths, from 8/500 to 30/500 – the latter being more potent.

As with the co-codamel painkiller that is currently being recalled, this strength of medication (30/500) is only available via prescription.

Thus, anybody who has been prescribed these tablets from the doctor needs to return the faulty batch 1K10121 to the pharmacy.

People who have bought co-codamel tablets at the supermarket won’t be affected by the latest safety recall.


This post originally appeared on Daily Express :: Health Feed
Read More

Some NP Thyroid Lots Recalled Due to Reduced Potency

In its third voluntary recall in the past year, Acella Pharmaceuticals has announced a nationwide recall of specific lots of its popular hypothyroid treatment NP Thyroid tablets USP, this time after routine testing found the pills to be subpotent.

Specifically, the affected lots were found to contain less than 90% of the drug’s two labeled ingredients to treat hypothyroidism: liothyronine (LT3) and/or levothyroxine (LT4).

The affected lots include 15-mg, 30-mg, 60-mg, 90-mg and 120-mg formulations of NP Thyroid tablets, packed in 100-count and 7-count bottles.

The list of the specific recalled lots is published on the Food and Drug Administration website.

Acella reports that, so far, 43 reports of serious adverse events that could be related to the recall have been received.

Symptoms suggesting patients may have received a subpotent batch include the common signs of hypothyroidism, such as fatigue, increased sensitivity to cold, constipation, dry skin, puffy face, hair loss, slow heart rate, depression, swelling of the thyroid gland and/or unexplained weight gain or difficulty losing weight, Acella reports.

“There is reasonable risk of serious injury in newborn infants or pregnant women with hypothyroidism including early miscarriage, fetal hyperthyroidism, and/or impairments to fetal neural and skeletal development,” the company cautions in the recall statement.

Acella adds that toxic cardiac manifestations of hyperthyroidism, including cardiac pain, palpitations or cardiac arrhythmia may occur in elderly patients and patients with underlying cardiac disease.

While Acella is notifying affected parties to discontinue distribution of the recalled products, it advises that patients who are currently taking NP Thyroid from the lots being recalled “should not discontinue use without contacting their healthcare provider for further guidance and/or a replacement prescription.”

In November 2020, a recall of NP Thyroid was issued after FDA testing found subpotent levels, as low as 87% of the labeled amount, of LT4 in some lots.

And earlier, in May 2020, the company recalled 13 lots of the tablets due to excessive potency, with FDA testing showing some tablets contained up to 115% of the labeled amount of LT3.

NP Thyroid is a type of desiccated animal thyroid product that was long the standard of care for hypothyroidism prior to the advent of the synthetic hypothyroidism drug, Synthroid (levothyroxine sodium), now the most commonly used hypothyroidism treatment.

On its website, Acella refers to NP Thyroid as a “natural choice for thyroid therapy,” as desiccated thyroid is commonly referred to.

However, one of the most common concerns about desiccated thyroid is a tendency to have unreliable concentrations of active ingredients, as discussed in American Thyroid Association recommendations.

The “amounts of both T4 and T3 can vary in every batch of desiccated thyroid, making it harder to keep blood levels right,” the ATA states.

“Finally, even desiccated thyroid pills have chemicals (binders) in them to hold the pill together, so they are not completely ‘natural.’ ”

Consumers with questions about the recall are advised to email Acella Pharmaceuticals at [email protected] or call 1-888-424-4341, Monday through Friday from 8:00 am to 5:00 pm ET.

This article originally appeared on MDedge.com, part of the Medscape Professional Network.

This post originally appeared on Medscape Medical News Headlines